RECURRENT BREAST CANCER IN A POSTMENOPAUSAL WOMAN (CLINICAL CASE)
Main Article Content
Abstract
Breast cancer is the most common malignant disease in women in the Russian Federation. In 2018, there were 70682 new cases, accounting for 20.9% of all malignant diseases in women. The average age of patients was 61.5 years. Over the past 10 years, the average annual growth rate of breast cancer (standardized rate) has been 1.97%. In recent years, there has been an increase in the number of patients diagnosed with breast cancer in the early stages. The standardized mortality rate decreased from 2008 to 2018, from 17.05 to 14.02, respectively. The risk of dying from breast cancer in women was 1.6% in 2018. The proportion of women who have been registered for 5 years or more is 59.8%. In the structure of female mortality, breast cancer also ranks first, accounting for 16.2%.
The presented article describes a clinical case of recurrent primary multiple breast cancer.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, et al. NCCN Guidelines Insights: Older Adult Oncology, Version 1.2021. J Natl Compr Canc Netw. 2021; 19(9): 1006-1019. doi: 10.6004/jnccn.2021.0043
Wang GL, Tsikouras P, Zuo HQ, Huang MQ, Peng L, Bothou A, et al. Radioactive seed localization and wire guided localization in breast cancer: A systematic review and meta-analysis. J BUON. 2019; 24(1): 48-60
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019; 37(19): 1629-1637. doi: 10.1200/JCO.18.01779
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019; 30(4): 558-566. doi: 10.1093/annonc/mdz012
Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019; 5(5): e190339-e190339. doi: 10.1001/jamaoncol.2019.0339
du Rusquec P, Blonz C, Frenel JS, Campone M. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Ther Adv Med Oncol. 2020; 12: 1758835920940939. doi: 10.1177/1758835920940939
Fares J, Kanojia D, Rashidi A, Ahmed AU, Balyasnikova IV, Lesniak MS. Diagnostic Clinical Trials in Breast Cancer Brain Metastases: Barriers and Innovations. Clin Breast Cancer. 2019; 19(6): 383-391. doi: 10.1016/j.clbc.2019.05.018
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020; 18(4): 452-478. doi: 10.6004/jnccn.2020.0016
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al. Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003- 11_CIBOMA/2004-01). J Clin Oncol. 2020; 38(3): 203-213. doi: 10.1200/JCO.20.00164
Suleman K, Almalik O, Haque E, Mushtaq A, Badran A, Alsayed A, et al. Does the Timing of Surgery after Neoadjuvant Therapy in Breast Cancer Patients Affect the Outcome? Oncology. 2020; 98(3): 168-173. doi: 10.1159/000504964
Yelgina SI, Ushakova GA, Nikulina EN. Reproductive system in full-term and preterm newborn girls. Fundamental and clinical medicine. 2016; 1(3): 39-45.) Russian (Елгина С.И., Ушакова Г.А., Никулина Е.Н. Репродуктивная система доношенных и недоношенных новорожденных девочек //Фундаментальная и клиническая медицина. 2016. Т. 1, № 3. С. 39-45)
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et. al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12): 1623-1649. doi: 10.1016/j.annonc.2020.09.010
Slamon DJ, Neven P, Chia S., Fasching PA, De Laurentiis М, Im SA, et. al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. Ann Oncol. 2020; 382(6): 514-524. doi: 10.1016/j.annonc.2020.09.010
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019; 5(1): 5. doi: 10.1038/s41523-018-0097-z